Profit before interest, taxes and amortization: g1therapeutics.com (GTHX)

G1 Therapeutics, Inc. revenues are based on the sale of a bone marrow protection drug and partnership royalties. The operating cash flow volume confirms this trend, where the value of shows the latest figure. Brand resilience is driven by physician confidence in the therapy's safety, although current restructuring and the freeze on new developments following the sale of a key asset create a technological vacuum.

This indicator measures the net daily cash flow from core operations before depreciation and interest, allowing for an assessment of the business's actual ability to generate cash. By analyzing the current EBITDA value, an investor can see how scaling sales of the drug Cosela reduces the impact of fixed R&D and marketing costs, turning operating leverage into a tool for profit growth for G1 Therapeutics, Inc. (GTHX).